Analyst Josh Jennings from TD Cowen reiterated a Buy rating on Dexcom and keeping the price target at $100.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Josh Jennings has given his Buy rating due to a combination of factors that suggest an attractive risk/reward setup for Dexcom’s stock. Concerns about the reliability of the G7 sensor have been exaggerated, and Jennings anticipates that the upcoming Q3 results will alleviate these worries, potentially leading to a recovery in the stock price by the end of the year.
Extensive checks indicate that the G7’s deployment and accuracy issues, which were most severe in the first half of the year, have largely been resolved. Feedback from key opinion leaders and improvements in product quality since June support this view. Dexcom’s management has also highlighted favorable trends in various performance metrics, reinforcing confidence in the company’s outlook. Jennings remains optimistic about the forthcoming Q4 results and 2026 guidance, further justifying the Buy rating.
Jennings covers the Healthcare sector, focusing on stocks such as TransMedics Group, Boston Scientific, and Medtronic. According to TipRanks, Jennings has an average return of 1.1% and a 47.39% success rate on recommended stocks.
In another report released on October 21, Stifel Nicolaus also initiated coverage with a Buy rating on the stock with a $85.00 price target.